362 related articles for article (PubMed ID: 26742710)
1. Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.
Fendler WP; Lechner H; Todica A; Paprottka KJ; Paprottka PM; Jakobs TF; Michl M; Bartenstein P; Lehner S; Haug AR
J Nucl Med; 2016 Apr; 57(4):517-23. PubMed ID: 26742710
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
3. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
5. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
Wong CY; Qing F; Savin M; Campbell J; Gates VL; Sherpa KM; Lewandowski RJ; Nagle C; Salem R
J Vasc Interv Radiol; 2005 Aug; 16(8):1101-6. PubMed ID: 16105922
[TBL] [Abstract][Full Text] [Related]
6. Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.
Michl M; Lehner S; Paprottka PM; Ilhan H; Bartenstein P; Heinemann V; Boeck S; Albert NL; Fendler WP
J Nucl Med; 2016 Mar; 57(3):355-60. PubMed ID: 26609176
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
Gunduz S; Ozgur O; Bozcuk H; Coşkun HS; Ozdogan M; Erkilic M; Sindel T; Yldlzs A; Ylmaz S; Boz A; Aydin F; Karayalçin B; Savas B
Hepatogastroenterology; 2014 Sep; 61(134):1529-34. PubMed ID: 25436337
[TBL] [Abstract][Full Text] [Related]
8. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
Saxena A; Kapoor J; Meteling B; Morris DL; Bester L
Ann Surg Oncol; 2014 Apr; 21(4):1296-303. PubMed ID: 24337647
[TBL] [Abstract][Full Text] [Related]
10. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
[TBL] [Abstract][Full Text] [Related]
11.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
12. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
[TBL] [Abstract][Full Text] [Related]
13. Total Lesion Glycolysis and Sequential (90)Y-Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Preliminary Results.
Bagni O; Filippi L; Pelle G; Cianni R; Schillaci O
Cancer Biother Radiopharm; 2015 Dec; 30(10):421-6. PubMed ID: 26594900
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
[TBL] [Abstract][Full Text] [Related]
15. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival.
Dunfee BL; Riaz A; Lewandowski RJ; Ibrahim S; Mulcahy MF; Ryu RK; Atassi B; Sato KT; Newman S; Omary RA; Benson A; Salem R
J Vasc Interv Radiol; 2010 Jan; 21(1):90-5. PubMed ID: 19939705
[TBL] [Abstract][Full Text] [Related]
17. Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization.
Sabet A; Ries M; Al-Khalaf Y; Meyer C; Rudlowski C; Simon B; Khreish F; Ezziddin S
Nuklearmedizin; 2019 Jun; 58(3):242-248. PubMed ID: 31167272
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
Kalva SP; Rana RS; Liu R; Rachamreddy N; Dave B; Sharma A; Ganguli S; Rabito C; Kwak E; Blaszkowsky LS
Am J Clin Oncol; 2017 Jun; 40(3):288-293. PubMed ID: 25374143
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.
Gordon AC; Gradishar WJ; Kaklamani VG; Thuluvath AJ; Ryu RK; Sato KT; Gates VL; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2014 Oct; 25(10):1523-32, 1532.e1-2. PubMed ID: 25156827
[TBL] [Abstract][Full Text] [Related]
20. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
